| 7.54 -0.24 (-3.08%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.94 | 1-year : | 11.21 |
| Resists | First : | 8.51 | Second : | 9.6 |
| Pivot price | 7.69  |
|||
| Supports | First : | 6.75 | Second : | 5.61 |
| MAs | MA(5) : | 7.76 |
MA(20) : | 7.77 |
| MA(100) : | 5.82 |
MA(250) : | 5.05 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 44.5 |
D(3) : | 49.2 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 9.6 | Low : | 3.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VNDA ] has closed above bottom band by 34.2%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.77 - 7.81 | 7.81 - 7.84 |
| Low: | 7.27 - 7.32 | 7.32 - 7.36 |
| Close: | 7.47 - 7.55 | 7.55 - 7.61 |
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Wed, 28 Jan 2026
Can Bysanti Redefine Vanda's Commercial Portfolio? - RTTNews
Tue, 27 Jan 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA - Chartmill
Thu, 08 Jan 2026
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Thu, 08 Jan 2026
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - PR Newswire
Fri, 02 Jan 2026
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 2,340 (K) |
| Shares Short P.Month | 4,640 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.88 |
| Profit Margin | -39.8 % |
| Operating Margin | -55.7 % |
| Return on Assets (ttm) | -12.2 % |
| Return on Equity (ttm) | -16.8 % |
| Qtrly Rev. Growth | 18.1 % |
| Gross Profit (p.s.) | 3.38 |
| Sales Per Share | 3.58 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -5.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.95 |
| Price to Sales | 2.1 |
| Price to Cash Flow | -5.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|